Global Ovarian Cancer Market "Set to Reach $6.7 BN by 2028"

The ovarian cancer market was valued at $1.8bn in 2018 across the seven major markets (US, France, Germany, Italy, Spain, UK, and Japan), and it is expected to grow to $6.7bn in the following 10 years, with a compound annual growth rate of 14.4%, according to GlobalData.   GlobalData’s latest report, Ovarian Cancer: Opportunity Analysis and Forecasts to 2028,¹ states that the main drivers of growth will be the adoption of maintenance therapy across the major markets, poly ADP-ribose polymerase (PARP) inhibitor uptake in the first-line setting, the launch of new pipeline agents, and increased screening rates for genetic markers.   In 2028, three PARP inhibitor drugs are expected to have combined revenue of $2.8bn, constituting more than 40% of the global ovarian cancer market. By 2028, another major revenue contributor will be new drug classes - notably, immune checkpoint inhibitors, with five expected to enter the market bringing combined forecasted revenues of around $1.4bn.   A major barrier for growth in the ovarian cancer market, however, will be the emerging use of biosimilars and generics for some key marketed products, namely Lynparza and angiogenesis inhibitor Avastin.     1. https://bit.ly/2PA1ItB